3 Life Science Stocks to Sell Now

Advertisement

For the current week, the overall ratings of three life science stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Enzo Biochem, Inc.’s (ENZ) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Enzo Biochem researches, develops, and manufactures health care products based on molecular biology and genetic engineering techniques. For Portfolio Grader’s specific subcategory of Equity, ENZ also gets an F. Shares of the stock have been changing hands at an unusually rapid pace, three times the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of ENZ stock.

This is a rough week for BG Medicin (BGMD). The company’s rating falls to D from the previous week’s C. BG Medicine develops and markets diagnostic tests. The stock gets F’s in Equity, Cash Flow and Sales Growth. Shares of the stock have been trading at an exceptionally rapid pace, up threefold from the week prior. To get an in-depth look at BGMD, get Portfolio Grader’s complete analysis of BGMD stock.

Slipping from a C to a D rating, Luminex Corporation (LMNX) takes a hit this week. Luminex develops, manufactures and markets biological testing technologies with applications throughout the clinical diagnostic and life science industries. The stock also rates an F in Earnings Revisions. For more information, get Portfolio Grader’s complete analysis of LMNX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/07/3-life-science-stocks-to-sell-now-enz-bgmd-lmnx-20/.

©2024 InvestorPlace Media, LLC